Assess of angiotensin receptor blockers therapy associated to mineralocorticoid receptor antagonists or to calcium channel blockers plus hydrochlorothiazide according central haemodynamic parameters

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Carlos Alberto Paterno Marchioli

Cardiovascular Research Laboratory., Castiglion Fiorentino (AR) (Italy)

14 More presentations in this session

Presentation thumbnail

Central-acting aminopeptidase a inhibitors for new treatment of hypertension: from discovery to clinical trial.

Doctor R. Hmazzou (Paris, FR)

Presentation thumbnail

Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: A 6-week randomised, multicentre, double-blind study followed by open-label phase

Doctor K. Bapatla (Hyderabad, IN)

Abstract Slides

Presentation thumbnail

Thrombin generation and platelet function in patients on RAAS inhibitors

Doctor C. Helten (Duesseldorf, DE)

Presentation thumbnail

Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: a cross-sectional study

Doctor E. Chowdhury (Perth, AU)

Abstract Slides

Presentation thumbnail

Hemodynamic management of resistant hypertension

Doctor F. Chacon-Lozsan (Budapest, HU)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 5 - Hypertension treatment: drugs and devices

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

The floor is yours: bring your questions about optimal blood pressure control for organ protection - expert panel

Congress Presentation

Hypertension, diabetes, and the kidney: a triple threat for adverse cardiovascular events?

Congress Presentation

Hypertension and glucose

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources